Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities

Conditions

• Attention Deficit Hyperactivity Disorder
• Down Syndrome
• Fragile X Syndrome
• Intellectual Disability

Eligibility Criteria

Sex

ALL

Age

6 Years - 24 Years

Healthy Volunteers

Not accepted

Interventions

• Methylphenidate Oral Solution — DRUG
  The XRMPH or matching placebo will be started at a dose of 0.3 mg/kg/day and individually titrated over two weeks. Phone calls at the end of weeks 1, 2, and 3 will be used to collect adverse event and response data. If there is no evidence of side effects and ongoing symptoms of ADHD, the dose will be increased to 0.5 mg/kg/day at one week and 0.7 mg/kg/day at 2 weeks (maximum dose of 60 mg per day consistent with FDA labeled use in youth).

Study Details

This study is a randomized, double-blind, placebo-controlled, crossover trial of extended-release liquid methylphenidate (XRMPH) to evaluate the sensitivity of the NIH Toolbox Cognition Battery (NIHTB-CB) to changes in cognition in children and adolescents ages 6 to 17 with intellectual disability (D) and comorbid Attention Deficit Hyperactivity Disorder (ADHD). The sample will include 68 males or females (expected male: female ratio of 1.8:1 with ID and ADHD as determined by structured diagnostic interview and Conners 3 scores. Additional inclusion criteria will include Full Scale IQ above 50 and mental age greater than or equal to 3 years. In addition, participants must be able to complete NIHTB-CB testing and provide valid scores at baseline. After baseline testing, participants will then be randomized to drug or placebo in a 1:1 ratio (N=34 per group) at the end of the baseline visit. XRMPH in oral suspension supplied as Quillivant XR in 5 mg/ml (Tris Pharma, Monmouth Junction, NJ) will be the active treatment. The XRMPH or matching placebo will be started at a dose of 0.3 mg/kg/day and individually titrated over two weeks. Phone calls at the end of weeks 1, 2, and 3 will be used to collect adverse event and response data. If there is no evidence of side effects and ongoing symptoms of ADHD, the dose will be increased to 0.5 mg/kg/day at one week and 0.7 mg/kg/day at 2 weeks (maximum dose of 60 mg per day consistent with FDA labeled use in youth). The Clinical Global Impression (CGI) will be used as a guide to define optimal dose. If side effects occur the dose will be reduced to the dose level at which there were no side effects. Final optimal dose will be established by the end of week 3 and this will be maintained for 2 weeks until 5 weeks post randomization, at which time the follow-up parent and teacher Conners scales, NIHTB-CB, Go/No-Go, and PedsQL will be completed. Participants will have a washout period of 1 week, will then complete re-assessment at the second baseline, and then will cross over to the other treatment (Quillivant to placebo; placebo to Quillivant), also in a double-blind fashion. In the second treatment arm, patients will have the same titration, monitoring and treatment periods as in the first arm, again followed by repeated assessments at the conclusion of 5 weeks. The accrual of participants and number of visits is shown in the Timeline per 6-month period.

Key Dates

Start date

Feb 1, 2023

Status verified

Dec 2025

Primary completion

Sep 29, 2026

Completion

Sep 29, 2026

Study Design

Enrollment

68 participants (estimated)

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

OTHER

Arms

• Active Comparator: Methylphenidate
• Placebo Comparator: Placebo

Primary Outcome Measure

Composite score of NIHTB-CB Flanker, Dimensional Change Card Sort, List Sorting and Speeded Matching tests. [ Time Frame: 11 weeks ]

Locations (3)

Find similar trials in Sacramento, CA

Related Studies

• Specimen Collection from Pregnant Women At Increased Risk for Fetal Aneuploidy
  Recruiting · Sequenom, Inc. · Birmingham, Alabama
• Computer Models of Airways in Children and Young Adults With Sleep Apnea and Down Syndrome
  Enrolling By Invitation · Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio
• Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD
  PHASE4 · Recruiting · Icahn School of Medicine at Mount Sinai · Gainesville, Florida
• Trial-Ready Cohort-Down Syndrome (TRC-DS)
  Recruiting · University of Southern California · Phoenix, Arizona